Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: A retrospective study

Authors

  • Luis Querol MD,

    1. Neuromuscular Diseases Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    2. Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
    Search for more papers by this author
  • Ricard Rojas-Garcia MD, PhD,

    1. Neuromuscular Diseases Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    2. Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
    Search for more papers by this author
  • Carlos Casasnovas MD,

    1. Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
    2. Neuromuscular Diseases Unit, Hospital Universitari de Bellvitge, Barcelona, Spain
    Search for more papers by this author
  • Maria Jose Sedano MD,

    1. Neurology Department, Hospital Universitario “Marques de Valdecilla”, Santander Spain
    Search for more papers by this author
  • Jose Luis Muñoz-Blanco MD,

    1. Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
    2. Neuromuscular Diseases and ALS Unit, Hospital Universitario Gregorio Marañón, Madrid, Spain
    Search for more papers by this author
  • Maria Antonia Alberti MD,

    1. Neuromuscular Diseases Unit, Hospital Universitari de Bellvitge, Barcelona, Spain
    Search for more papers by this author
  • Carmen Paradas MD, PhD,

    1. Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
    2. Neuromuscular Diseases Unit, Hospital Universitario Virgen del Rocío, Sevilla, Spain
    Search for more papers by this author
  • Teresa Sevilla MD,

    1. Neurology Department, Hospital Universitari I Politècnic La Fe, Valencia, Spain
    Search for more papers by this author
  • Julio Pardo MD,

    1. Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
    2. Neurology Department, Hospital Universitario de Santiago, Santiago de Compostela, Spain
    Search for more papers by this author
  • Jose Luis Capablo MD,

    1. Neurology Department, Hospital Universitario “Miguel Servet”, Zaragoza, Spain
    Search for more papers by this author
  • Rafael Sivera MD,

    1. Neurology Department, Hospital Universitari I Politècnic La Fe, Valencia, Spain
    Search for more papers by this author
  • Antonio Guerrero MD,

    1. Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
    2. Neuromuscular Diseases and ALS Unit, Hospital Clinico “San Carlos”, Madrid, Spain
    Search for more papers by this author
  • Eduardo Gutierrez-Rivas MD,

    1. Neurology Department, Hospital Universitario “12 de Octubre”, Madrid, Spain
    Search for more papers by this author
  • Isabel Illa MD, PhD

    Corresponding author
    1. Neuromuscular Diseases Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    2. Centro Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
    Search for more papers by this author

  • This study was funded by Grifols S.A (Barcelona, Spain), Fondo de Investigaciones Sanitarias (Project FIS 09/1964), CIBERNED (Database Project No. AC631), and by a research grant as part of the Rio Hortega program (Project No. FIS CM 09/00017 to L.Q.).

ABSTRACT

Introduction: The objective of this retrospective study was to describe the short- and long-term patterns of IVIg use, safety, and response to treatment in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Methods: Response to therapy was defined as an improvement of ≥1 point on the modified Rankin score at short- and mid-term visits. Patient status at long term was classified as remission, stability, or non-responder. Results: Eighty-six patients were included; 60.5% responded at short term and 54.6% at mid-term. At long term, 25.6% of patients were in remission, 65.1% were stable, and 9.3% were non-responders. The only variable associated with remission was a better response during the first 6 months of follow-up. Conclusions: A significant percentage of patients did not require any additional drugs in the long term. This suggests that treatment effect or disease outcome may be stable over time, and treatment regimens should therefore be individualized to avoid overtreatment. Muscle Nerve 48: 870–876, 2013

Ancillary